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Background: Morbidity and mortality from primary varicella-zoster virus (VZV) infection is increased in
immunocompromised children. Vaccination of VZV-seronegative cancer patients with live-attenuated
varicella vaccine is safe when chemotherapy is interrupted. However, VZV vaccinationwithout interrup-
tion of chemotherapy would be preferable.
Objective: To vaccinate VZV-seronegative pediatric oncology patients with live-attenuated VZV vaccine
without interrupting their chemotherapy.
Study-design: We performed a single-center prospective cohort study.
Results: Thirty-one patients with either a hematological malignancy (n=24) or a solid tumor (n=7) were
vaccinated early during their course of chemotherapy. VZV IgG seroconversion occurred in 14 of the 31
patients (45%) after one vaccination. Only 20 patients were revaccinated after 3 months. These were
patients who did not seroconvert (5 patients) and patients who serocoverted (15 patients) to induce or
sustain seropositivity. Of these 20 patients the ﬁnal seroconversion rate was 70%. Seven out of the 31
patients (23%) developed a mild rash of which 5 were treated with antivirals and recovered completely
without interrupting chemotherapy, and 2 recovered untreated. Of these 31 immunized patients 26were
available for cellular testing. After one vaccination 20 of 26 patients (77%) tested positive for VZV-speciﬁc
+CD4 T cells, of which 7 patients had remained VZV-seronegative. After the second vaccination 11 of 11
patients showed VZV-speciﬁc CD4+ T cells to sustain positivity, although 4 remained VZV-seronegative.
Conclusions: This study indicates that live-attenuated VZV vaccine can be safely administered to closely
monitored pediatric oncology patients without interruption of chemotherapy and adaptive immunity
was induced despite incomplete seroconversion.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license. Background
Varicella (chickenpox) is a highly infectious, usually self-limited
isease caused by the varicella-zoster virus (VZV). In the past the
omplication-rate of chickenpox in children with a malignancy
as approximately 30% [1–3]. With antiviral therapy the outcome
mproved, the overall mortality currently is 0.05–1% [4–7]. 25%
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of pediatric oncology patients encounter chickenpox during treat-
ment and 16-20% of these patients will experience morbidity due
to complications of this infection [4,8]. Approval of live-attenuated
varicella vaccine in the USA was in 1995 for routine use in healthy
persons older than one year of age who are susceptible to VZV.
Other countries followed shortly and Japan, Korea and most states
of the USA have included varicella vaccination in their national
vaccination schedule. The vaccine induces long-term humoral and
cellular immunity in children and adults [9,10]. Since the imple-
mentation of VZV vaccination, a marked decline in the number of
cases of varicella and a trend towards less hospitalizations due to
chickenpox has been observed [11].
However not all children are vaccinated. It would be of great
beneﬁt to vaccinate VZV-seronegative oncology patients.We know
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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hat vaccination of leukemia patients in remission is feasible
12]. Although cell-mediated immunity is elicited less reliably in
eukemic children after varicella vaccination than in healthy chil-
ren, it appeared that the administration of VZV vaccine under
ontrolled conditions canbebeneﬁcial to leukemicpatients [12,13].
ne would prefer to vaccinate in the early phase of treatment,
s reported in a small pilot study achieving a seroconversion
ate of 77% [13]. Mild side-effects were observed in 12.5% of the
atients consisting of a varicelliform rash and fever. However, in
his study chemotherapeutic treatment was delayed in order to
accinate the children. Vaccination of patients with lymphocytes
700/mm3,without stopping chemotherapy andwithout interrup-
ion of steroids 14 days before vaccination until one week after
accination, led to an unacceptably high incidence of complica-
ions and severe rashes [14–16], and one fatal case [17]. Prevention
f chickenpox during treatment for a malignant disorder remains
n important goal, while considering feasibility and safety as the
ajor guiding principles.
.1. Objective
To investigate the safety and efﬁcacy of VZV vaccination of VZV-
eronegative pediatric oncology patients, without interruption of
hemotherapy, and respecting the rule not to vaccinate during the
hase in which steroids are given, or when a low number of circu-
ating lymphocytes is present.
.2. Study design
.2.1. Patient selection
Newly diagnosed pediatric oncology patients who tested neg-
tive for VZV IgG antibodies and were never vaccinated before
gainst VZV, were included in this single-center study at the
cademic Medical Centre in Amsterdam, The Netherlands. Eli-
ibility criteria included hematological and solid tumor patients
n chemotherapy, who had circulating lymphocyte counts of
700/mm3, without bulky disease and without septicemia at the
ime of vaccination. All children were treated according to Euro-
ean protocols included in the DCOG (Dutch Cancer Oncology
roup) database. VZV vaccination was administered in a steroid-
ree phase of the treatment regimens one week before and one
eek after vaccination. The study was approved by the local med-
cal ethical committee. Written informed consents were obtained
rom the parents of the patients and from the patient if 12 years of
ge or older.
.2.2. Vaccination protocol
Varicella vaccine (Varilrix, GlaxoSmithKline UK, Uxbridge, UK;
ontaining the attenuated VZV Oka-strain) was administered sub-
utaneously to eligible patients (day 0). A second dose of the
accine was given at 3 months after the ﬁrst dose. Clinical param-
ters were registered on the base of questionnaires and physical
xamination on day 0, 7, 14, 21, 28 and 3 months after vaccina-
ion. Parameters recorded by the questionnaires included: fever
>39 ◦C), headache, vomiting, diarrhea (deﬁned as >6 loose stools
day), coughing, and pain, rash or induration at the injection-site.
arameters recorded on physical examination included: tempera-
ure, organomegaly (upon vaccination), skin lesions, and signs of
nfection. Standard laboratory tests were performed, including a
omplete blood cell count (CBC), creatinine, and liver enzymes. To
etermine the immunological response to vaccination, peripheral
lood samples were drawn from the patients at each visit. Periph-
ral bloodmononuclear cells (PBMCs)were isolated frombloodand
ryopreserved until analysis. To monitor infectivity of the vacci-linical Virology 75 (2016) 47–52
nated patients, throat-swabs were taken twice a week, for 6 weeks
following the ﬁrst vaccination.
1.2.3. Laboratory parameters for VZV infection
VZV speciﬁc IgG seroreactivity was determined qualitatively
using a varicella-zoster IgG assay, following the instructions of the
manufacturer. (miniVidas, Biomerieux, Marcy l’Etoile, France. VZV
IgG was positive for sample-to-standard-ratios ≥0.90; equivocal
between 0.60 and 0.90; and negative when <0.60). The equivocal
results will be regarded as positive Quantitative PCR (qPCR) for the
viral load was performed in blood samples and in throat swabs as
described before [18].
1.2.4. Immunoﬂuorescent staining and ﬂow cytometry
PBMCs were used to determine the absolute numbers and
percentages of CD4+ and CD8+ T cells, B cells and NK cells
(MultiTest IMK kit, BectonDickinson [BD] Biosciences, Franklin
Lakes, NJ, USA). Using 20l of the multiset antibody mix, either
CD3/CD8/CD45/CD4 or CD3/CD16CD56/CD45/CD19 was added to
50l blood in two different TruCount tubes (BD). Cell viability was
determined after freeze-thawing and the absolute numbers and
percentages of lymphocyte cell populations were determined by
theMultiset program (BD) on a FACSCalibur (BD), 6×105 T cells per
stimulus were used. Controls were included in each experiment.
1.2.5. Determination of VZV-speciﬁc T cells by proliferation
For antigen-speciﬁc T-cell activation VZV-antigen was used in
a ﬁnal concentration of 20l/ml, previously deﬁned as the opti-
mal dose for stimulation of PBMCs [19]. For proliferation, PBMCs
at 5–10×106 cells/ml were labeled with 0.5M (ﬁnal concentra-
tion) of 5,6-carboxyﬂuorescein diacetate succinimidyl ester (CFSE;
Molecular Probes, Paisley, UK), washed and resuspended in culture
medium for six days. T cells were stimulated with VZV-antigen,
combination of CD3/CD28 MoAbs at saturating concentrations
as described before [20].
1.2.6. Statistics
SPSS 20.0 was used as data base and analysis tool. Where appli-
cable, differences between means were tested by Student t-test.
Because of the small sample sizemost datawere described descrip-
tively.
2. Results
2.1. Patient characteristics
Thirty one VZV-seronegative pediatric oncology patients were
included in this study from February 2002 until May 2010 with for
each patient a minimum of 5 years of follow-up for the children
who survived. All children were treated according to DCOG (Dutch
Cancer Oncology group) included protocols. Patient characteristics
are presented in Table 1. Chemotherapywasnot stoppedordelayed
because of VZV vaccination.
2.2. Laboratory results
White cell counts and liver enzymes of the patients are summa-
rized in Table 2. The hematology patients had higher liver enzymes
as compared to the patients with solid tumors, although the differ-
ence did not reach signiﬁcance. The hematology patients received
high doses of methotrexate, which can explain the elevated liver
enzymes. The liver enzymes normalized in all patientswithin three
months after vaccination. No signiﬁcant differences in the num-
bers of CBCs, lymphocytes or neutrophilswere detected comparing
patientswithahematologicalmalignancyora solid tumor (Table2).
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Table 1
Patient characteristics.
Patients (N) = 31 Hematology 24
Solid 7
Age (years) Hematology 4.1 (2.9–16.9) P=0.57 (NS)
(At time of vaccination) Solid 2.9 (1.8–5.3)
Time (weeks)
Start chemotherapy to ﬁrst vaccination (mean) Hematology 14.2 (6–36) P=0.75 (NS)
Solid 18.5 (8–36)
Adverse effects
Skin lesions (number of patients) Hematology 5 (21%) P=0.67 (NS)
Solid 2 (28%)
Treatment with antivirals (number of patients)
Hematology 4 (16.6%) P=0.88 (NS)
Solid 1 (14.2%)
Seroconversion
1st vaccination (n=31) Hematology (24) 10 (41.5%) Total 14 (45%)
Solid (7) 4 (57.2)%
2nd vaccination (n=20) Hematology (15) 10 (67%) Total 14 (70%)
Solid (5) 4 (80%)
Table 2
Laboratory results as mean (range) on day 1 of ﬁrst vaccination.
Hematology N=24 Solid N=7 P value
Neutrophils (x106/l) 2382 (770–4650) 2576 (240–6000) P=0.71 (NS)
Lymphocytes (x106/l) 2190 (700–6830) 1151 (400–2700) P=0.11 (NS)
White cell count (x109/l) 5.4 (1.8–10.2) 5.1 (3.8–7.8) P=0.76 (NS)
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Table 3
VZV-speciﬁc CD4+ T-cell activity after the ﬁrst and second vaccination.
Vaccination 1 (n=26) Seronegative Seropositive
T-cell positive 7 13 20
T-cell negative 5 1 6
Total 12 14 26
Vaccination 2 (n=11) Seronegative seropositive
T-cell positive 4 7 11ALAT (IU) 106 (14–820) 41.8 (20–88) P=0.39 (NS)
ASAT (IU) 118 (14–519) 43.3 (22–62) P=0.24 (NS)
.3. Adverse effects and virology
To determine whether the patients were contagious after vac-
ination, VZV was monitored for 6 weeks following the ﬁrst
accination. VZV-DNA was detected by PCR in all 4 throat swabs
f these patients, while viral cultures taken in parallel all remained
egative.
In 6 of the 31 vaccinated patients VZV DNA became detectable
n peripheral blood within 6 weeks after vaccination (median peak
alue 7500 VZV DNA copies/ml, range 40–10,000 copies/ml). No
ousehold exposure to chickenpox was documented during this
eriod. Five of these 6 viremic patients seroconverted in response
o the ﬁrst vaccination.
In 7 patients (22.5%) mild adverse effects were observed within
0 days after vaccination. They developed a rash (<50 vesicles).
ccording to the clinical score of Vazquez et al. [21], all 7 patients
ere considered to havemild disease. Four of these 7 patientswere
reated with oral valacyclovir (total of 7 days); 1 with intravenous
cyclovirbecauseofmucositis (total of7days)whichprecludedoral
edication; and 2 patients did not receive antiviral treatment. All
patients with adverse effects after vaccination recoveredwithout
nterruption of chemotherapy.
.4. Immunogenicity of the vaccination
VZV-speciﬁc IgG could be detected in 14 of the 31 patients (45%)
fter theﬁrst vaccination. Themajority of these patients (80%) sero-
onverted within 6 weeks after VZV vaccination. Seroconversion
id not correlate with the age at vaccination (p=0.35), the time
etween start of chemotherapy and vaccination (p=0.49), or with
he number of circulating lymphocytes at the time of vaccination
p=0.19). Twenty patients received a second dose of vaccine. The
emaining 11 patients were not vaccinated a second time because
f various reasons, ranging from no consent from the parents for
he second vaccination, to patient related reasons, such as a relapse
f the primary disease, making re-vaccination too risky. After the
econd dose of vaccine in 20 patients (3 months after the initial
ose), the IgG seroconversion rate increased to 70% (Fig. 1). OfT-cell negative 0 0 0
Total 4 7 11
these 14 patients 4 converted from IgG-seronegative to seropos-
itive, 5 converted from borderline seropositivity to seropositive,
and remainingpatientswere already IgG-seropositive after theﬁrst
vaccination and consented to receive a second vaccination to fur-
ther sustain positivity.
During the ﬁrst year after chemotherapy, environmental or
household contacts to wild-type VZV were documented in 5
patients (16%). The ﬁrst patient (1 vaccination IgG seronegative
but positive VZV-speciﬁc CD4+ T-cell activity) showed no clini-
cal signs of varicella upon contact and was therefore not treated.
The 4 other patients all vaccinated twice all seronegative after ﬁrst
vaccination, 2 seropositive after 2 vaccinations and all showed pos-
itive VZV-speciﬁc CD4+ T-cell activity (all hematological patients)
developed a varicelliform rash (50–200 lesions) and reported their
varicella contact within 3 days after chickenpox exposure (6–12
months after VZV vaccination) were treated as soon as vesicles
appeared. Twohad aVazquez-score of 13 and appearedmoderately
ill (the seronegative patients after 2 vaccinations). Both recovered
rapidly after start of acyclovir intravenously, having in retrospect a
relatively normal viral load (wild-type VZV-DNA loads peaking at
12,000 and 42,500 copies/ml) [18]. The 2 other patients (seroposi-
tive patients after 2 vaccinations) had a Vasquez-score <7 andwere
treatedwithoral valacyclovir.All thesepatients showedamitigated
clinical course as compared to an IgG-negative immunocompro-
mised patient with wild-type VZV infection in another study, who
had not been vaccinated and showed a viral load up to 1,000,000
copies/ml [22].
2.5. Occurrence of VZV-speciﬁc CD4+ T cells
A VZV-speciﬁc CD4+ T-cell proliferation assay could be per-
formed in 26 patients after the ﬁrst vaccination, of which 13
patients showed seroconversion and T cell positivity (Table 3,
Fig. 1). Twenty of these 26 patients showed VZV-speciﬁc CD4+ T-
cell reactivity (of which 7 were VZV-IgG negative) (Fig. 2A and
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amples.
upplementary Figure). After a second vaccination the assay could
e performed in 11 patients, all 11 patients (4 remained IgG-
eronegative) showed VZV-speciﬁc T-cell proliferation (Table 3,
ig. 2A). The assay could not be completed in all patients because of
ack of blood samples; examples of kinetics in VZV-speciﬁc T-cell
esponses over timehave been added for reasons of clarity (Fig. 2B).
. Discussion
This is the ﬁrst report of a cohort of pediatric oncology patients
ho received live-attenuatedVZVvaccine in a relatively early stage
f treatment without interrupting chemotherapy. The criteria that
o steroids are given one week before and one week after vaccina-
ion, lymphocyte counts should be >700/mm3, and that the child
as no bulky disease, were all met. Adverse effects of vaccinationr of patients of whom VZV T-cell reactivity has been tested in the available blood
in our cohort were limited to a mild rash observed in 7 patients
(22.5%), accompanied by fever in 3 patients (9.6%). The occurrence
of adverse effects in these patients did not correlate with the num-
ber of circulating lymphocytes on the ﬁrst day of vaccination. All
patients recovered without interrupting chemotherapy. We are
aware of the possible bias thatwewere extremely cautious looking
for these side effects possibly treating them very early. Although
seroconversion rates after a single dose of vaccine were lower in
our cohort compared to the LaRussa cohort (45% vs. 82%) [12], the
data from the present study are encouraging since severe disease
in this susceptible population did not occur following vaccination
during or after chemotherapy.
Upon infection, VZV is believed to be contained by the concerted
actionof antibodies, T cells andNKcells [23–25]. Itwas encouraging
to ﬁnd that out of 26 patients tested for VZV-speciﬁc T-cell activ-
M.D. van de Wetering et al. / Journal of C
Fig. 2. VZV-speciﬁc T-cell reactivity.
A: Bargraph representing VZV-speciﬁc CD4 + T-cell proliferation in IgG-positive and
IgG-negative patients as shown for primary and secondary VZV immunizations.
B: Time curves in three patients with different patterns of humoral and T-cell reac-
tivity. The upper panel illustrates a case with a steady rise in positive IgG titer at 3
and 6 months. The middle panel represents a case with marginal IgG response at 3
months, IgG-negative at 6 months following vaccinations—being IgG-positive at 1
year of follow-up in the absence of documented chickenpox contact or overt clinical
breakthrough infection. The lower panel represents a case with negative IgG at 3
months and positive IgG titer at 6 months post-vaccination.linical Virology 75 (2016) 47–52 51
ity 77% were found positive after the ﬁrst immunization and that
of these 66% showed seroconversion. After a second vaccination
100% of the patients tested showed VZV-speciﬁc T-cell activity at
a similar seroconversion rate. In 5 patients who developed wild-
type varicella during follow-up the varicella vaccination seemed to
protect from the development of severe disease, however it is likely
that the vaccinees reported exposure and disease sooner thanmost
other immune compromised children would have, since they were
informed about this as part of the study, andwere probably treated
sooner.
But in our experience, as well as previously described in
literature [26,27], unvaccinated cancer patients develop severe
chickenpox upon exposure. In the patients with exposure to chick-
enpox who developed a mitigated course of varicella, we noticed
that virus-speciﬁc T cells were clearly induced within 14 days
after appearance of the rash (own patients). These data suggest
a suboptimal induction of adaptive immunity upon immunization,
rather than primary vaccine failure. VZV-speciﬁc CD4+ T cells were
induced upon vaccination, after 2 vaccinations even in 100% of the
analyzed patients (total of 11 patients). In this respect, it is known
that VZV-speciﬁc CD4+ T cells can be detected in healthy children
upon vaccination and also show the response that they develop less
severe varicella on exposure [28]. Leukemic patients develop less
pronounced VZV-speciﬁc T-cell responses upon chickenpox infec-
tion [25]. Therefore, the frequencies of these cells are higher in
healthy children than in our patients, which are detected by their
antigen-speciﬁc proliferative T-cell responses.
Potential transmission of the attenuated VZV strain to other
immunocompromised children was stringently monitored yet not
encountered.AlthoughVZV-DNAwasdetectedbyPCRatborderline
levels in 4 throat swabs from 4 patients upon weekly monitor-
ing, the viral cultures from the oropharynx taken in parallel all
remainednegative. Thisﬁnding is inaccordancewith theﬁndings in
oropharyngeal secretions from vaccinated controls [29]. However,
thevaccinatedpatients thatdevelopcutaneousvesicular lesionsare
infectious from these lesions as proven by viral culture of vesicle
ﬂuids or scrapings. In this group of patients precautions for isola-
tion need to be taken,such as protective isolation although the virus
will still be live-attenuated to its close contacts [29].
For unvaccinated and vulnerable patients such as pediatric
oncology patients, a well-targeted VZV vaccination strategy, such
as the one applied in this study, seems promising under close
monitoring. After VZV vaccination, the clinician may decide to
withhold preventive measures such as the intramuscular admin-
istration of VZV-speciﬁc antibodies upon VZV contact, even when
the immunocompromised patient has remained seronegative after
2 vaccinations. The patient’s T-cell reactivity is likely to prevent
severe varicella, and if varicella would be clinically progressive,
valacyclovir or acyclovir may be administered.
Our study demonstrates that a varicella vaccination strategy in
the newly non-vaccinated IgG-negative pediatric oncology patient
is possible, without interruption of chemotherapy, showing sero-
conversionof70%after2vaccinations. This strategyoffering2doses
will need to be conﬁrmed in a larger study. In this larger study
follow up data on persistence of antibody levels to indicate how
good immune memory is needs to be performed.
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